Suman Kambhampati is an Oncology physician. ClinicalTrials.gov lists 3 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
4801 E Linwood Blvd
Veteran Affairs Medical Center, Research #517
Kansas City, MO 641282226
Telephone
816-861-4700Provider last certified this registry record 27 May 2025.
Clinical trials
- Castrate Resistant Prostate Cancer Enhertu Therapy
Sponsor: Washington D.C. Veterans Affairs Medical Center
- A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Sponsor: VA Office of Research and Development
- Phase I and II Study of Auranofin in Chronic Lymphocytic Leukemia (CLL)
Sponsor: University of Kansas Medical Center
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
15 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ADC THERAPEUTICS AMERICA, INC.Program year20251 payment
- GENZYME CORPORATIONProgram year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20251 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Cancer & immunology
49.2%Thalidomide Analog26.9%Revlimid53%Pomalyst27%Lenalidomide19%Part D<11 patientsKinase inhibitor13.8%Imbruvica49%Brukinsa27%Tasigna24%Part D<11 patients+ 2 more classes in this area
Dermatology
20.8%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor20.8%Acyclovir100%Part D≥20 patientsNervous system
13.1%Gabapentinoids9.5%Gabapentin100%Part D<11 patientsSSRI3.7%Escitalopram Oxalate100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
1 NIH research award on record, funded 2025–2025 per NIH RePORTER. The latest:
- Benefit of Venetoclax Addition ("Benefit VA") in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Kansas City Va Medical Center
FY2025I01CX002685
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
Freddie Bray
Centre National de la Recherche Scientifique
Jacques Ferlay
Centre international de recherche sur le cancer
Hermann Brenner
German Cancer Research Center
Isabelle Soerjomataram
Centre international de recherche sur le cancer
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”